The FDA has approved the combination of lurbinectedin (Zepzelca) and atezolizumab (Tecentriq) as a first-line maintenance treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) ...

Dr. Gerrina Ruiter discusses zongertinib's promising efficacy in treating HER2-mutant NSCLC, highlighting its unique effectiveness against brain metastases.

Chandler H. Park, MD, a medical oncologist at Norton Cancer Institute and advisory dean/professor at University of Louisville in Kentucky, discusses the Category 1 treatment options for metastatic ...

AMXT 1501 is a novel polyamine transport inhibitor designed to block the uptake of polyamines, therefore working to stop the growth and survival of tumors. DFMO is an irreversible inhibitor of ...

Belantamab mafodotin (Blenrep), pomalidomide (Pomalyst), and dexamethasone (BPd) was well tolerated and led to deep responses in patients with high-risk multiple myeloma.

Discover how El Camino Health's multidisciplinary approach enhances cancer care for younger adults, featuring collaboration among diverse medical specialists. In an interview with Targeted Oncology, ...

Gerrina Ruiter, MD, PhD, highlights the Beamion LUNG-1 study's impact on treating HER2-mutant non-small cell lung cancer with ...

Cevostamab showed a 93% MRD-negative complete response rate at 1 year post CAR T-cell therapy in heavily pretreated multiple myeloma patients. Cevostamab delivered feasible and well-tolerated ...

One patient has glioblastoma multiforme (GBM), and the other patient has advanced hepatocellular carcinoma (HCC) treated in the second line. Neither patient has experienced PIC-related adverse events ...

Innovative DNA-based immunotherapy shows promise, achieving over five years of recurrence-free survival in patients with aggressive brain and liver cancers.

With this feedback from the FDA, IO Biotech has announced it intends to continue correspondence with the FDA for alignment on design for a potential new registrational study. Additionally, they plan ...

The ESMO 2025 Congress will highlight late-breaking abstracts on RCC and bladder cancer, focusing on immune checkpoint ...